Real-time enrollment status for this relapsed/refractory hematopoietic malignancies, acute myeloid leukemia and mds clinical trial
Current Status
Recruiting
Checked: August 31, 2026 at 3:39 AM UTC
| NCT Number | NCT02203903 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS |
| Phase | PHASE1 |
| Target Enrollment | 50 participants |
| Active Locations | 2 sites in the US |
| Sponsor | Catherine Bollard |
| Last Updated on CT.gov | August 14, 2026 (2 weeks ago) |
As of August 31, 2026: Clinical trial NCT02203903 is currently recruiting participants. This phase1 study for relapsed/refractory hematopoietic malignancies, acute myeloid leukemia and mds is actively seeking new participants at 2 locations across the United States. The study is sponsored by Catherine Bollard. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT02203903 is actively recruiting participants as of August 31, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 2 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT02203903 was last updated 2 weeks ago (August 14, 2026). HelloStudys verifies this status automatically.